NCT05171647 2026-03-06
SUNMO
Hoffmann-La Roche
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT06084936 2026-03-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT04408638 2026-01-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04361552 2020-06-18
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
Phase 3 Withdrawn
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT00883753 2014-08-06
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT01209689 2013-01-17
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
Hoffmann-La Roche
Phase 3 Terminated